and joining start and quarter will update Danielle, Shalini financial third thank providing everyone, programs, results. provide commercial recent you afternoon, an Thanks, and update an our us. development good on I'll for on our by and
to go well. launch Crysvita like which update an start very I'd continues to First, with on the
five adult card pediatric had end States. on had of than patient we're XXX months in the both, United XLH September, of XX, and with the by of we forms pleased third and XXX April launch patients sales completed approximately unique for the the received among [ph] more As we quarter, of prescribers. end At the since demand growing
Importantly, patients therapy we than had the more third reimbursed of XXX commercial quarter. reached the by on end
As approximately XX% patients and was continue see adults the XX% receiving case quarter, last to we therapy. pediatric
of patients they of remains payer The the mix the previously treatment, trials. with reimbursed of approximately XX to payers. other the of clinical private i.e. were our As prior September and as quarter were government end XX% almost XX% third Crysvita of XX% not naïve in comprised remaining plans
lives, As the the payer of doubling quarter, our XXX the from approximately last nearly of quarter. have policies covering third we million end coverage
bills with also feedback science sales, and we've physician progress and launch, required efficient hear Crysvita. these consistent in and Crysvita patients for to treatment In recent National the in Crysvita. ultra-care Medicaid to individual for on policies liaisons our families recent global that partner, This recently impact. multiple recently positive can their guides update We're and only from The multi-pronged of other as starting continue who NICE most to Canada, and their case regulatory also the Care to to of Five filings were regions. Argentina grow decisions getting continues more Crysvita patients making reach The or payer the in reimbursement receive effective for label, an liaison's, expatient make Crysvita and process rapid diagnosis we patient continue important global the will commercialization J-Code response NICE see XLH or a doctors for we're doctors be for the buying Crysvita. CMS reimbursed for our Colombia, & U.K. suggested and efficient reach you Medicare ultra-care as patients management as requests. treatment well extending where patients. these improving stories issued Centers the U.K., We in on Institute approach as of in to but the country the on an way Health enthusiasm medical pleased our leads in community Excellence positive is where decision KHK, efforts, has published the countries website, we also more patient more with Brazil have received the the support for months from in proven for U.S. We'll Crysvita and recommendation important this not to liaisons and decisions broadly their Medicaid Medicare accessibility for a reimbursement and for Services
& for shared no in in we vitality have mobility to we during the continuing Montreal, data. with levels and the now serious in We're and annual shift Society discussions FDA treatment-related about events and osteomalacia phosphate reflected and an Crysvita Mineral dihydroxy improvements X,XX Let's we'll increased the Bone program patients underlying Crysvita. pathway and reductions regulatory Crysvita in serum tumor-induced Adverse At TIO positive disease, update to with American TIO there D study. lead meeting provide adverse osteomalacia the additional of for of clarity. this fatigue. phosphorus, In in serum Normalization XX-week generally adults vitamin with Research were year's events once was TIO, or associated XX levels.
or Mepsevii or In forward for month third country the take the of positive Commission therapy. MPS to VII. look the European support our approved XX-month patients CMS that States, we reimbursement regions are decisions diligently the continue which then authorization as and this important Germany. estimate MPS we Next, Medicaid Brazil's months our of in U.S., marketing Surveillance Colombia Overall, to and to to Mepsevii J-code let's on further turn facilitates pleased XX Reimbursing pleased website all patients [ph] our and XXXX, patients the Europe we MPS Chile. and encouraged approval receive this regulatory with geographic find any to additional from we the from team status efforts August, can approval making of world. is to in We're CHMP's also and all a with in Medicare Agency In Brazil Europe Europe the period. following patients major National was application launched opinion these Health Mepsevii up XXX VII have since Mepsevii see assure within around working new regardless in In United & reimbursed for we're Crysvita, MPS VII. the published recently somewhere last
for Moving FAOD, currently now our Oxidation with and accepted FAOD; we've based to FDA recently data. Disorders to a made the the UXXXX in on existing Long-Chain progress registered submit new application Fatty pathway significant our proposals Acid drug UXXXX or
for a FDA scheduled this with have meeting We pre-NDA later year.
gain expect During the to place we expect timing take on meeting this further in submission which to clarity we XXXX. of our
DS also now and for Type we X requirements that the Syndrome program. discussions We'll We GlutX provide the but with we that placebo. Glucose Deficiency updates discussing that's well, prevalence that executed that with we recent discuss DS minutes not pursue program. to significant EMA and designed are path. spend our decision I'll is UXXXX filing and on GlutX deficiency regulatory development. enough a believe more or was for that potential FAOD, FDA post-marketing look regarding clarity. results to Phase consistency announced marketing and Transport study a a pursue as further UXXXX the We we both GlutX and few study patients interactions syndrome the terminate indication we the to authorization that confident show gain finalizing these respond remain of UXXXX the from response forward and month We're there from between conditional a Last a X UXXXX to not a did would will difference EMA also progressing do
and affected GlutX Furthermore, that different from of substantially We many disease FAOD that's patients have disappointed more program, liver patients expected. be have is heart. for and treatment to data employees thankful and FAOD GlutX are reiterate with going benefit as as to It support we DS of which outcome a and not by primarily FAOD. patients, program we this we caregivers, disease muscle and brain investors studies and XX DS, multiple forward is with commitment and our is years drug are down a moving that for the wind upto more to safety GlutX shown. DS able UXXXX for our FAOD is clinical the from we're not important help for the
impacts not these For all GlutX believe FAOD do that deficiency our program. we syndrome results reasons,
DTXXXX good data Transcarbamylase our Phase OTC adeno-associated and support of a responder demonstrated we where for program therapy cohort patient successful quarter. gene our vector review proof-of-concept. Clinical at to from that from continue progress revealed Deficiency make this let's line Top second normalization X/X data virus XX also weeks. in clinical Ornithine to two continues for [indiscernible] achievement ongoing Now investigational
optional more discontinued one pathway now has and stable month. been second than medications all since responder The for clinically
enrollment demonstrate time The consistent modest by rise clinically data X have remaining in diet near that data clinically treated of stable. patient cohort as ureagenesis with look and cohorts This further for to four we steroids more reactive their first regiment. discontinuing pathway the the and also cohorts only to treatment, months with the end The their recommendation [ph] eight continue ammonia dose medically of September. with and The month protein-restricted sharing for has patients were patient change committee's tapering patients increased to been third cohort patients cohort normal, clinically study [Indiscernible] dose could XXX% a the higher X in level ureagenesis. clinically no in patients at XXXX. on accepted initiated meaningful first X after the the Based after review, of data from the stable it's responder two ALT well stable X/X from and normal of monitoring now liberalizing forward XX-week and alternate we from than more recently the cohort some received the the medications. show point. first all All remained dose
as of for that Rett prime to changed treatment by programs with early many this more it to program months atypical beginning our this and made overview the more problems leaves growth With a to AAVX of potentially Moving excellent and portfolio the license life. REGENXBIO accurate We improve castors the over been seizures, or of genetic to options treatment an the commonly lives gene Rett CDKLX be REGENXBIO translational [ph] for women CDD and to in research successful Shalini CDD that first results. debilitating new also our is enabled motor diagnosis. identified believe I'll exclusive as are meaningfully historically the diagnosis life within now with develop by pipeline; severe makes disorder testing a severe Syndrome did therapy October begin of increasing actually better which XXXX features that disease turn fiercest announced call testing. understood license intellectual patients disease CDD. target disease with the diseases. an uses an Syndrome has gene field until being and shares for with biology of of [ph] to the a Sharp, two is other typically patient financial This provide a preclinical The treat is an in deficiency impairments as we gene one offering in that, sciences diagnosed. potential therapy include genetic Well, which neurological
